001     292341
005     20250826100541.0
024 7 _ |a pmid:39163805
|2 pmid
024 7 _ |a 0720-048X
|2 ISSN
024 7 _ |a 1872-7727
|2 ISSN
024 7 _ |a 10.1016/j.ejrad.2024.111679
|2 doi
024 7 _ |a altmetric:166580751
|2 altmetric
037 _ _ |a DKFZ-2024-01692
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Mascalchi, Mario
|0 P:(DE-He78)eba11eff7c9c475da132d5343d569759
|b 0
|e First author
245 _ _ |a Large cell carcinoma of the lung: LDCT features and survival in screen-detected cases.
260 _ _ |a Amsterdam [u.a.]
|c 2024
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1725371832_17193
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C020#LA:C020#
520 _ _ |a To investigate the early radiological features and survival of Large Cell Carcinoma (LCC) cases diagnosed in low-dose computed tomography (LDCT) screening trials.Two radiologists jointly reviewed the radiological features of screen-detected LCCs observed in NLST, ITALUNG, and LUSI trials between 2002 and 2016, comprising a total of 29,744 subjects who underwent 3-5 annual screening LDCT examinations. Survival or causes of death were established according to the mortality registries extending more than 12 years since randomization.LCC was diagnosed in 30 (4 %) of 750 subjects with screen-detected lung cancer (LC), including 15 prevalent and 15 incident cases. Three additional LCCs occurred as interval cancers during the screening period. LDCT images were available for 29 cases of screen-detected LCCs, and 28 showed a single, peripheral, and well-defined solid nodule or mass with regularly smooth (39 %), lobulated (43 %), or spiculated (18 %) margins. One case presented as hilar mass. In 9 incident LCCs, smaller solid nodules were identified in prior LDCT examinations, allowing us to calculate a mean Volume Doubling Time (VDT) of 98.7 ± 47.8 days. The overall five-year survival rate was 50 %, with a significant (p = 0.0001) difference between stages I-II (75 % alive) and stages III-IV (10 % alive).LCC is a fast-growing neoplasm that can escape detection by annual LDCT screening. LCC typically presents as a single solid peripheral nodule or mass, often with lobulated margins, and exhibits a short VDT. The 5-year survival reflects the stage at diagnosis.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a ITALUNG
|2 Other
650 _ 7 |a LUSI
|2 Other
650 _ 7 |a Large cell carcinoma
|2 Other
650 _ 7 |a Low dose CT
|2 Other
650 _ 7 |a Lung cancer
|2 Other
650 _ 7 |a NLST
|2 Other
650 _ 7 |a Screening
|2 Other
650 _ 7 |a Survival
|2 Other
700 1 _ |a Puliti, Donella
|b 1
700 1 _ |a Cavigli, Edoardo
|b 2
700 1 _ |a Cortés-Ibáñez, Francisco O
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Picozzi, Giulia
|b 4
700 1 _ |a Carrozzi, Laura
|b 5
700 1 _ |a Gorini, Giuseppe
|b 6
700 1 _ |a Delorme, Stefan
|0 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
|b 7
|u dkfz
700 1 _ |a Zompatori, Maurizio
|b 8
700 1 _ |a Raffaella De Luca, Giulia
|b 9
700 1 _ |a Diciotti, Stefano
|b 10
700 1 _ |a Eva Comin, Camilla
|b 11
700 1 _ |a Alì, Greta
|b 12
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 13
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.ejrad.2024.111679
|g Vol. 179
|0 PERI:(DE-600)2005350-2
|p 111679
|t European journal of radiology
|v 179
|y 2024
|x 0720-048X
856 4 _ |u https://inrepo02.dkfz.de/record/292341/files/1-s2.0-S0720048X24003954-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/292341/files/1-s2.0-S0720048X24003954-main.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:292341
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)eba11eff7c9c475da132d5343d569759
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-26
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J RADIOL : 2022
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-26
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 1
920 0 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21